The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment

Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment

March 31, 2020 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Sanofi and Regeneron Pharmaceuticals Inc. have expanded a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a coronavirus treatment to patients outside the U.S.

You Might Also Like
  • Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment
  • Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug
  • Regeneron Plans Early Summer Trials for New Antibodies Against Coronavirus

The companies said enrolments for the mid-to-late stage trial of sarilumab, an immune-system modifying drug known as a monoclonal antibody, have now started in Italy, Spain, Germany, France, Canada and Russia. The U.S. trials began last week.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The trial, expected to enroll about 300 patients, will recruit hospitalized patients from several countries who are severely or critically ill with COVID-19 infection, a disease caused by the highly contagious novel coronavirus SARS-CoV-2.

The new coronavirus has now infected more than 700,000 people worldwide, and over 30,000 people have died from it, according to a Reuters tally.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Doctors have seen that many of those who become critically ill from SARS-CoV-2 are experiencing a so-called cytokine storm, which happens when the immune system overreacts and attacks the body’s organs. Some researchers think drugs that can suppress the immune system, including monoclonal antibodies, may be useful for limiting this autoimmune response.

The U.S. has the most reported cases of any country in the world, with more than 130,000 cases of COVID-19.

Italy and Spain have been two of the worse-hit countries in Europe, recording the highest and the second highest death toll from coronavirus of any country in the world, respectively.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Regeneron is leading the U.S. trials, while Sanofi is leading trials outside the U.S.

Filed Under: Drug Updates Tagged With: clinical trials, COVID-19, Regeneron Pharmaceuticals Inc., Sanofi, sarilumab

You Might Also Like:
  • Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment
  • Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug
  • Regeneron Plans Early Summer Trials for New Antibodies Against Coronavirus
  • Trial of Gilead’s Potential Coronavirus Treatment Running Ahead of Schedule

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.